Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): Evidence and perspectives

Journal of Thoracic Disease

Volumn 8, Issue 10, 2016, Pages 2666-2671

  Rendon, Adrian ^a,b   Tiberi, Simon ^c   Scardigli, Anna ^d   D'Ambrosio, Lia ^e,f   Centis, Rosella ^e   Caminero, Jose A ^g   Migliori, Giovanni Battista ^e  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b Latin American Thoracic Association (ALAT)   (United States)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d TUBERCULOSIS AND MALARIA   (Switzerland)

^e IRCCS   (Italy)

^f Public Health Consulting Group SAGL   (Switzerland)

^g HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; LINEZOLID; TUBERCULOSTATIC AGENT;

CLINICAL EFFECTIVENESS; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HISTORY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE;

EID: 84995400115     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/jtd.2016.10.14     Document Type: Editorial

References (39)

1. World Health Organization. Global tuberculosis report. 2015. Available online: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf
2. Caminero JA, Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J 2015;46:887-93
3. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015;45:928-52
4. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014;43:1410-20
5. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-68
6. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013;42:169-79
7. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. Available online: http://www.who.int/tb/MDRTBguidelines2016.pdf
8. Sotgiu G, Tiberi S, D'Ambrosio L, et al. Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. Eur Respir J 2016. [Epub ahead of print]
9. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28
10. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-9
11. Caminero JA. editor. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. Paris, France: International Union Against Tuberculosis and Lung Disease, 2013
12. Cambau E, Viveiros M, Machado D, et al. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J Antimicrob Chemother 2015;70:686-96
13. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009;4:e6914
14. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40:1430-42
15. Chang KC, Yew WW, Tam CM, et al. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013;57:4097-104
16. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18
17. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015;45:161-70
18. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2011;38:730-3
19. De Lorenzo S, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. Eur Respir J 2012;39:770-2
20. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015;45:25-9
21. Sotgiu G, Centis R, D'Ambrosio L, et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J 2015;45:287-9
22. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012;16:447-54
23. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013;42:1449-53
24. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016;47:394-402
25. Tadolini M, Garcia-Prats AJ, D'Ambrosio L, et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J 2016;48:938-43
26. Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016;48:935-8
27. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405
28. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723-32
29. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014;43:289-92
30. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60
31. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393-400
32. Wells CD, Gupta R, Hittel N, et al. Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid. Eur Respir J 2015;45:1498-501
33. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014;44:811-5
34. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013;41:1386-92
35. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clin Infect Dis 2016;62:1188-90
36. Tiberi S, Payen MC, Sotgiu G, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR-and XDR-TB. Eur Respir J 2016;47:1235-43
37. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR-and XDR-TB. Eur Respir J 2016;47:1758-66
38. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 2016;47:333-6
39. Diacon AH, van der Merwe L, Barnard M, et al. β-Lactams against Tuberculosis-New Trick for an Old Dog? N Engl J Med 2016;375:393-4